1. Home
  2. FLYW vs NUVB Comparison

FLYW vs NUVB Comparison

Compare FLYW & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

HOLD

Current Price

$18.55

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.67

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYW
NUVB
Founded
2009
2018
Country
United States
United States
Employees
N/A
307
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
FLYW
NUVB
Price
$18.55
$5.67
Analyst Decision
Buy
Strong Buy
Analyst Count
14
8
Target Price
$16.21
$11.38
AVG Volume (30 Days)
2.6M
8.5M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
N/A
EPS
0.10
N/A
Revenue
$623,025,000.00
N/A
Revenue This Year
$19.68
$203.82
Revenue Next Year
$15.25
$58.18
P/E Ratio
$183.30
N/A
Revenue Growth
26.59
N/A
52 Week Low
$10.11
$2.06
52 Week High
$18.92
$9.75

Technical Indicators

Market Signals
Indicator
FLYW
NUVB
Relative Strength Index (RSI) 69.87 56.87
Support Level $13.15 $4.13
Resistance Level N/A $6.06
Average True Range (ATR) 0.76 0.40
MACD 0.27 -0.02
Stochastic Oscillator 88.11 42.81

Price Performance

Historical Comparison
FLYW
NUVB

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: